Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trialAdrian F. Hernandez, Lauren B. Cooper, Christopher B. Granger et al.|The Lancet|2018Cited by 1.8k
Comparative efficacy, safety, and cardiovascular outcomes with once-weekly subcutaneous semaglutide in the treatment of type 2 diabetes: Insights from the SUSTAIN 1–7 trialsVanita R. Aroda, Ildiko Lingvay, Andrew Ahmann et al.|Diabetes & Metabolism|2019Cited by 281